Retatrutide has emerged as a new medication in the fight against obesity. This revolutionary drug, classified as a dual GLP-1 custom peptides and GIP receptor agonist, demonstrates promising results in research studies. By stimulating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately leads to significant r